CME · 10-Q · 2026Q2 · Full report

Acquisition / Partnership / Divestiture

CME GROUP INC. · 2026-07-24 · Importance 63 · Surprise 50

CME Group sold its OSTTRA joint venture during the fourth quarter of 2025. The sale reduced second-quarter 2026 equity in net earnings from unconsolidated subsidiaries because OSTTRA no longer contributed earnings. Six-month equity in net earnings increased to $200.1 million from $187.2 million, primarily because of higher income from the S&P Dow Jones Indices LLC business venture.

Key facts

• Equity in net earnings of unconsolidated subsidiaries increased in the first six months of 2026 due in part to higher income from S&P Dow Jones Indices LLC and was lower in Q2 2026 due to the sale of the OSTTRA joint venture in Q4 2025. source